Dear Biopharma Manufacturers: Your At-Risk Day Has Arrived
The writing has been on the wall from some time. The push for value-based care has had a domino effect…
DetailsThe top 4 things you should know about the state of HIV treatment
What are the new questions regarding HIV treatment? When it comes to hepatitis C, Gilead drugs Harvoni and Sovaldi have…
DetailsNew Curant Cares Award Recognizes Employee Morale
For employees at Curant Health, caring for patients is a fundamental job role. Advocating on behalf of our patients, verifying…
DetailsThe Who and What of ACG 2015
ACG 2015 was a remarkable mixture of clinicians, manufacturers and medical device companies focused on the sharing the new processes,…
DetailsHow to smooth the patient access path to life-altering therapies
The newly approved PCSK9 inhibitors are a major advance in cholesterol-lowering drug therapy. Gregory Curfman, MD and Editor in Chief of…
Details3 reasons to stop bashing biopharmaceutical manufacturers
“Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates…
DetailsKey considerations in negotiating at-risk contracts
All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to…
DetailsWalk with Curant for cures and HIV treatment
We’ve talked about who we are: Curant Health is a team of healthcare experts who provide individualized, patient-centered services proven…
DetailsWhat biopharmaceutical manufacturers really want in network partnerships
As the creation of new drugs for chronic illness progresses, we ask ourselves certain questions when thinking from a biopharmaceutical…
DetailsThe 80/20 Rule of Healthcare Spending
There’s an 80/20 rule when it comes to healthcare – 80% of healthcare cost comes from 20% of the populace,…
Details